(Q28270037)

IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells

published in

Monoclonal Antibodies

0 references

volume

1

0 references

issue

3

0 references

page(s)

237-46

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Eat dirt: CpG DNA and immunomodulation of asthma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

20 March 2017

IL-13 effector functions

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

20 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Interleukin-13: central mediator of allergic asthma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Mepolizumab and exacerbations of refractory eosinophilic asthma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Induction, function and regulation of IL-17-producing T cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

The IL-17 cytokine family and their role in allergic inflammation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

New targets for drug development in asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Treatment of chronic autoimmune urticaria with omalizumab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Lung dendritic cells: targets for therapy in allergic disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

The development of allergic inflammation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Treatment strategies for allergy and asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Targeting TNF-alpha: a novel therapeutic approach for asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Epithelium: at the interface of innate and adaptive immune responses

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Cytokines and growth factors in airway remodeling in asthma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Transient regulatory T-cells: a state attained by all activated human T-cells.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Role of cytokines in allergic airway inflammation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

TLR9-based immunotherapy for allergic disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Therapeutic potential of Toll-like receptor 9 activation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Modifying toll-like receptor 9 signaling for therapeutic use.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Airway remodeling contributes to the progressive loss of lung function in asthma: an overview

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

The role of dendritic cells in asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

IL-13 receptors and signaling pathways: An evolving web

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Eosinophilia in transgenic mice expressing interleukin 5.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Requirement for IL-13 independently of IL-4 in experimental asthma

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.

20 June 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

IL-33 is a chemoattractant for human Th2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Antibody against interleukin-5 prevents antigen-induced eosinophil infiltration and bronchial hyperreactivity in the guinea pig airways

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Eosinophils in asthma--closing the loop or opening the door?

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Interleukin-13 in asthma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Effect of omalizumab in health care workers with occupational latex allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Evidence of a role of tumor necrosis factor alpha in refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.3.8352

Mechanisms of Fc epsilon RI-IgE-facilitated allergen presentation by dendritic cells.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726591

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

27 November 2018

1 reference

12 December 2020

Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma

1 reference

12 December 2020

Omalizumab also successful in chronic urticaria

1 reference

12 December 2020

Omalizumab in severe chronic urticaria

1 reference

12 December 2020

Omalizumab for patients with severe and therapy-refractory atopic eczema?

1 reference

12 December 2020

Omalizumab and Churg-Strauss syndrome

1 reference

12 December 2020

Apparent response to anti-IgE therapy in two patients with refractory "forme fruste" of Churg-Strauss syndrome

1 reference

12 December 2020

Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial

1 reference

12 December 2020

Therapeutic alternatives for chronic urticaria: additional reports on omalizumab

1 reference

12 December 2020

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis

1 reference

12 December 2020

High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflammation?

1 reference

12 December 2020

Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients

1 reference

12 December 2020

Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response

1 reference

12 December 2020

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

1 reference

12 December 2020

The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma

1 reference

12 December 2020

The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma

1 reference

12 December 2020

Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis

1 reference

12 December 2020

Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response

1 reference

12 December 2020

T lymphocyte activation in acute severe asthma

1 reference

12 December 2020

The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation

1 reference

12 December 2020

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

12 December 2020